It's certainly interesting. Not sure what to make of it yet. I've seen some negative things about how it is an anti-psychotic, but it doesn't block the same dopamine receptors as the more common antipsychotics. (Ecopipam blocks D1, others block D2) The guy leading the research (Gerald Maguire) is a stuttering and I do trust him to carry out this research accurately and thoroughly. This paper is a great review of Ecopipam and how it compares to other therapies: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118465/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118465/)